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Background: Adverse drug reactions (ADRs) caused by fluoropyrimidines depend, at
least in part, from DPD deficiency resulting from the loss-of-function mutations
c.1905 + 1G > A and c.2846A > T. Moreover, irinotecan ADRs appear frequently in
patients bearing the UGT1A1*28 variant, associated with reduced UGT1A1 expression.
In this study, we analyse the association between DPYD and UGT variants with ADRs
by 5-fluorouracil and irinotecan in subjects enrolled within the phase III TRIBE study,
whose final results have been recently reported.
Methods: Out of 508 randomized patients, blood samples for pharmacogenetic
analyses were available for 440 patients. DNAwas extracted from 200 µl of blood and
analyses of DPYD c.1905 + 1G > A, c.2846T > C and UGT1A1*28 was performed by a
Pyrosequencing platform (Qiagen, USA). The study was approved by the local Ethics
Committee.
Results: Each of the DPYD c.1905 + 1GA and c.2846AT genotypes were found in 5 out
of 440 subjects, with a combined frequency of 2.2%. c.1905 + 1GA and c.2846AT had
the same impact on ADRs and, taken together, patients bearing these variants (N = 10)
had an increased risk of G3/4 neutropenia (OR: 4.14, p = 0.043) and stomatitis (OR:
10.36, p = 0.003) as compared to wild-type patients. Five out of 10 DPYD mutant
patients experienced a G4 ADR after the first cycle of therapy. UGT1A1*28/*28 was
found in 39/436 patients (8.9%); these patients had an increased risk of G3/4
neutropenia as compared to both *1/*1 (OR: 3.81, p < 0.001) and *1/*28 (OR: 2.28,
p = 0.022) genotypes. Patients bearing DPYD c.1905 + 1GA, c.2846AT and
UGT1A1*28/*28 (N = 49) had an increased risk of G3/4 neutropenia (OR: 2.98,
p < 0.001), febrile neutropenia (OR: 2.78, p = 0.023) and G3/4 stomatitis (OR: 6.83,
p < 0.001). No significant correlation with G3/4 diarrhea was found.
Conclusions: DPYD c.1905 + 1GA, c.2846AT and UGT1A1*28/*28 are associated with
a higher risk of G3/4 ADRs also in the TRIBE trial, underscoring the predictive role of
DPYD and UGT1A1 variants across various fluoropyrimidine and
irinotecan-containing schedules, and therefore their potential usefulness in treatment
tailoring.
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